Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Int J Mol Sci ; 20(9)2019 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-31052404

RESUMEN

Vulvodynia is a remarkably prevalent chronic pain condition of unknown etiology. An increase in numbers of vulvar mast cells often accompanies a clinical diagnosis of vulvodynia and a history of allergies amplifies the risk of developing this condition. We previously showed that repeated exposures to oxazolone dissolved in ethanol on the labiar skin of mice led to persistent genital sensitivity to pressure and a sustained increase in labiar mast cells. Here we sensitized female mice to the hapten dinitrofluorobenzene (DNFB) dissolved in saline on their flanks, and subsequently challenged them with the same hapten or saline vehicle alone for ten consecutive days either on labiar skin or in the vaginal canal. We evaluated tactile ano-genital sensitivity, and tissue inflammation at serial timepoints. DNFB-challenged mice developed significant, persistent tactile sensitivity. Allergic sites showed mast cell accumulation, infiltration of resident memory CD8+CD103+ T cells, early, localized increases in eosinophils and neutrophils, and sustained elevation of serum Immunoglobulin E (IgE). Therapeutic intra-vaginal administration of Δ9-tetrahydrocannabinol (THC) reduced mast cell accumulation and tactile sensitivity. Mast cell-targeted therapeutic strategies may therefore provide new ways to manage and treat vulvar pain potentially instigated by repeated allergenic exposures.


Asunto(s)
Analgésicos no Narcóticos/uso terapéutico , Dronabinol/uso terapéutico , Hipersensibilidad/complicaciones , Mastocitos/efectos de los fármacos , Tacto , Vulvodinia/tratamiento farmacológico , Analgésicos no Narcóticos/farmacología , Animales , Dinitrofluorobenceno/toxicidad , Dronabinol/farmacología , Femenino , Inmunoglobulina E/sangre , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Mastocitos/inmunología , Ratones , Vulvodinia/etiología , Vulvodinia/fisiopatología
2.
Int J Mol Sci ; 20(21)2019 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-31661848

RESUMEN

A history of allergies doubles the risk of vulvodynia-a chronic pain condition of unknown etiology often accompanied by increases in numbers of vulvar mast cells. We previously established the biological plausibility of this relationship in mouse models where repeated exposures to the allergens oxazolone or dinitrofluorobenzene on the labiar skin or inside the vaginal canal of ND4 Swiss Webster outbred mice led to persistent tactile sensitivity and local increases in mast cells. In these models, depletion of mast cells alleviated pain. While exposure to cleaning chemicals has been connected to elevated vulvodynia risk, no single agent has been linked to adverse outcomes. We sensitized female mice to methylisothiazolinone (MI)-a biocide preservative ubiquitous in cosmetics and cleaners-dissolved in saline on their flanks, and subsequently challenged them with MI or saline for ten consecutive days in the vaginal canal. MI-challenged mice developed persistent tactile sensitivity, increased vaginal mast cells and eosinophils, and had higher serum Immunoglobulin E. Therapeutic and preventive intra-vaginal administration of Δ9-tetrahydrocannabinol reduced mast cell accumulation and tactile sensitivity. MI is known to cause skin and airway irritation in humans, and here we provide the first pre-clinical evidence that repeated MI exposures can also provoke allergy-driven genital pain.


Asunto(s)
Cosméticos/toxicidad , Dermatitis Alérgica por Contacto/etiología , Mastocitos/efectos de los fármacos , Conservadores Farmacéuticos/toxicidad , Tiazoles/toxicidad , Vagina/efectos de los fármacos , Alérgenos , Animales , Dermatitis Alérgica por Contacto/tratamiento farmacológico , Dermatitis Alérgica por Contacto/epidemiología , Dronabinol/uso terapéutico , Femenino , Humanos , Inmunoglobulina E/sangre , Mastocitos/metabolismo , Ratones , Membrana Mucosa , Dolor/inducido químicamente , Piel , Vagina/inmunología
3.
Cancer Res ; 84(4): 577-597, 2024 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-37967363

RESUMEN

RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop-associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription-replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer. SIGNIFICANCE: Spliceosome-mutant leukemias accumulate R-loops and require PARP1 to resolve transcription-replication conflicts and genomic instability, providing rationale to repurpose FDA-approved PARP inhibitors for patients carrying spliceosome gene mutations.


Asunto(s)
Leucemia , Empalmosomas , Humanos , Empalmosomas/genética , Estructuras R-Loop , Inhibidores de Poli(ADP-Ribosa) Polimerasas/farmacología , Inhibidores de Poli(ADP-Ribosa) Polimerasas/uso terapéutico , Reparación del ADN , Leucemia/tratamiento farmacológico , Leucemia/genética , Factores de Empalme de ARN/genética , Poli(ADP-Ribosa) Polimerasa-1/genética
4.
Bioorg Med Chem ; 20(13): 4128-39, 2012 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-22626552

RESUMEN

A novel 4-aminocyclopentapyrrolidine series of N-type Ca(2+) channel blockers have been discovered. Enantioselective synthesis of the 4-aminocyclopentapyrrolidines was enabled using N-tert-butyl sulfinamide chemistry. SAR studies demonstrate selectivity over L-type Ca(2+) channels. N-type Ca(2+) channel blockade was confirmed using electrophysiological recording techniques. Compound 25 is an N-type Ca(2+) channel blocker that produces antinociception in inflammatory and nociceptive pain models without exhibiting cardiovascular or motor liabilities.


Asunto(s)
Acetamidas/síntesis química , Analgésicos/síntesis química , Bloqueadores de los Canales de Calcio/síntesis química , Canales de Calcio Tipo N/química , Pirrolidinas/química , Pirrolidinas/síntesis química , Acetamidas/farmacología , Acetamidas/uso terapéutico , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Conducta Animal/efectos de los fármacos , Bloqueadores de los Canales de Calcio/farmacología , Bloqueadores de los Canales de Calcio/uso terapéutico , Canales de Calcio Tipo N/metabolismo , Modelos Animales de Enfermedad , Masculino , Dolor/tratamiento farmacológico , Pirrolidinas/farmacología , Pirrolidinas/uso terapéutico , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad
5.
ACS Omega ; 7(5): 3872-3880, 2022 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-35155884

RESUMEN

In this research, we perform a theoretical interpretation of molecular and electronic properties of reduced graphene oxide (rGO) nanoflakes through the density functional theory. Here, two pristine graphene nanoflake systems were passivated by hydrogen atoms at their edges, armchair (C58H20) and zigzag (C54H20); besides, we implemented 12 rGO systems with a range of low oxide coverage (1, 3, and 4%). Computational calculations were carried out employing the functional hybrid B3LYP and the basis 6-31G(d, p) and 6-311G(d, p) levels of theory. We brought the proposed molecular structures to a stable minimum. We determined the global reactivity descriptors through chemical potential, hardness, softness, and index of electrophilicity. Besides, the maps of electrostatic potential were generated. We found that the hydroxyl and epoxy functional groups dope the graphene molecule in p-type and n-type forms, respectively. In addition, we could attribute the increases of the oxide coverage and the chemical potential to the softness of the molecule. These results suggest that structures with this type of doping can help in developing advanced electronics of sensors and devices.

6.
Neurooncol Adv ; 3(1): vdab102, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34549181

RESUMEN

BACKGROUND: The adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data. METHODS­PRECLINICAL STUDY: The impact of tumor size on ADC tumor delivery and treatment response was evaluated in an EGFR-amplified patient-derived glioblastoma (GBM) model following treatment with Depatuxizumab mafadotin (Depatux-M). Biodistribution and imaging studies correlated drug distribution with starting treatment volume and anti-tumor activity. METHODS­CLINICAL STUDY: M12-356 was a Phase I study of Depatux-M in patients with GBM. Blinded volumetric analysis of baseline tumor volumes of M12-356 patients was undertaken by two reviewers and results correlated with response and survival. RESULTS: Preclinically, imaging and biodistribution studies showed specific and significantly higher tumor uptake of zirconium-89 labeled Depatux-M (89Zr-Depatux-M) in mice with smaller tumor volume (~98 mm3) versus those with larger volumes (~365 mm3); concordantly, mice with tumor volumes ≤100 mm3 at treatment commencement had significantly better growth inhibition by Depatux-M (93% vs 27%, P < .001) and significantly longer overall survival (P < .0001) compared to tumors ≥400 mm3. Clinically, patients with tumor volumes <25 cm3 had significantly higher response rates (17% vs. 0%, P = .009) and longer overall survival (0.5 vs 0.89 years, P = .001) than tumors above 25 cm3. CONCLUSION: Both preclinical and clinical data showed intra-tumoral concentration and efficacy of Depatux-m inversely correlated with tumor size. This finding merit further investigation with pretreatment tumor volume as a predictor for response to ADCs, in both gliomas and other solid tumors.

7.
PLoS One ; 15(10): e0241218, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33104726

RESUMEN

Occupational exposure to toxic chemicals increases the risk of developing localized provoked vulvodynia-a prevalent, yet poorly understood, chronic condition characterized by sensitivity to touch and pressure, and accumulation of mast cells in painful tissues. Here, we topically sensitized female ND4 Swiss mice to the common household and industrial preservative methylisothiazolinone (MI) and subsequently challenged them daily with MI or acetone and olive oil vehicle on the labiar skin. MI-challenged mice developed significant, persistent tactile sensitivity and long-lasting local accumulation of mast cells alongside early, transient increases in CD4+ and CD8+ T cells, eosinophils, neutrophils, and increases in pro-inflammatory cytokines. Therapeutic administration of imatinib, a c-Kit inhibitor known to inhibit mast cell survival, led to reduced mast cell accumulation and alleviated tactile genital pain. We provide the first pre-clinical evidence of dermal MI-induced mast-cell dependent pain and lay the groundwork for detailed understanding of these intersections between MI-driven immunomodulation and chronic pain.


Asunto(s)
Dolor Crónico/etiología , Dermatitis por Contacto/etiología , Desinfectantes/toxicidad , Inflamación/etiología , Tiazoles/toxicidad , Animales , Femenino , Inflamación/inmunología , Mastocitos/inmunología , Ratones , Piel/efectos de los fármacos , Piel/patología
8.
Clin Cancer Res ; 25(11): 3259-3265, 2019 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-30796037

RESUMEN

PURPOSE: Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential therapeutic target, we systematically evaluated methods of assessing EGFR amplification by multiple assays. Specifically, we evaluated correlation among fluorescence in situ hybridization (FISH), a standard assay for detecting EGFR amplification, with other methods.Experimental Design: Formalin-fixed, paraffin-embedded tumor samples were used for all assays. EGFR amplification was detected using FISH (N = 206) and whole-exome sequencing (WES, N = 74). EGFR mRNA expression was measured using reverse transcription-polymerase chain reaction (RT-PCR, N = 206) and transcriptome profiling (RNAseq, N = 64). EGFR protein expression was determined by immunohistochemistry (IHC, N = 34). Significant correlations among various methods were determined using Cohen's kappa (κ = 0.61-0.80 defines substantial agreement) or R 2 statistics. RESULTS: EGFR mRNA expression levels by RNA sequencing (RNAseq) and RT-PCR were highly correlated with EGFR amplification assessed by FISH (κ = 0.702). High concordance was also observed when comparing FISH to WES (κ = 0.739). RNA expression was superior to protein expression in delineating EGFR amplification. CONCLUSIONS: Methods for assessing EGFR mRNA expression (RT-PCR, RNAseq) and copy number (WES), but not protein expression (IHC), can be used as surrogates for EGFR amplification (FISH) in GBM. Collectively, our results provide enhanced understanding of available screening options for patients, which may help guide EGFR-targeted therapeutic approaches.


Asunto(s)
Biomarcadores de Tumor , Glioblastoma/etiología , Medicina de Precisión , Ensayos Clínicos Fase I como Asunto , Receptores ErbB/genética , Receptores ErbB/metabolismo , Amplificación de Genes , Perfilación de la Expresión Génica , Pruebas Genéticas , Glioblastoma/diagnóstico , Glioblastoma/metabolismo , Glioblastoma/terapia , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Medicina de Precisión/métodos , Medicina de Precisión/normas , Reacción en Cadena en Tiempo Real de la Polimerasa , Secuenciación del Exoma
9.
Neuro Oncol ; 21(1): 106-114, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-29982805

RESUMEN

Background: Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells with EGFR amplification, is internalized, and releases a microtubule toxin, killing the cell. Here we report efficacy, safety and pharmacokinetics (PK) of depatux-m + temozolomide (TMZ) in patients with EGFR-amplified rGBM. Methods: M12-356 (NCT01800695) was an open-label study encompassing patients with newly diagnosed or rGBM across 3 treatment arms. Results are reported for adults with EGFR-amplified, measurable rGBM who received depatux-m (0.5-1.5 mg/kg) on days 1 and 15, and TMZ (150-200 mg/m2) on days 1-5 in a 28-day cycle. Patients were bevacizumab and nitrosourea naïve. Results: There were 60 patients, median age 56 years (range, 20-79). Fifty-nine patients previously received TMZ. Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%). Grades 3/4 AEs were split between ocular and non-ocular AEs, occurring in 22% of patients each. Systemic PK exposure of depatux-m was dose proportional. The objective response rate was 14.3%, the 6-month progression-free survival rate was 25.2%, and the 6-month overall survival rate was 69.1%. Conclusions: Depatux-m + TMZ displayed an AE profile similar to what was described previously. Antitumor activity in this TMZ-refractory population was encouraging. Continued study of depatux-m in patients with EGFR-amplified, newly diagnosed, or recurrent GBM is ongoing in 2 global, randomized trials (NCT02573324, NCT02343406).


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Amplificación de Genes , Glioblastoma/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Adulto , Anciano , Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Estudios de Cohortes , Receptores ErbB/genética , Femenino , Estudios de Seguimiento , Glioblastoma/genética , Glioblastoma/patología , Humanos , Agencias Internacionales , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Recurrencia Local de Neoplasia/genética , Recurrencia Local de Neoplasia/patología , Pronóstico , Temozolomida/administración & dosificación , Distribución Tisular , Adulto Joven
10.
Neuro Oncol ; 20(6): 838-847, 2018 05 18.
Artículo en Inglés | MEDLINE | ID: mdl-29077941

RESUMEN

Background: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of depatux-m, either in combination with temozolomide in newly diagnosed or recurrent glioblastoma (arm B) or as monotherapy in recurrent glioblastoma (arm C). Methods: In this multicenter phase I dose escalation study, patients received depatux-m (0.5-1.5 mg/kg in arm B, 1.25 mg/kg in arm C) every 2 weeks by intravenous infusion. Maximum tolerated dose (MTD), recommended phase II dose (RP2D), and preliminary efficacy were also determined. Results: Thirty-eight patients were enrolled as of March 1, 2016. The most frequent toxicities were ocular, occurring in 35/38 (92%) patients. Keratitis was the most common grade 3 adverse event observed in 6/38 (16%) patients; thrombocytopenia was the most common grade 4 event seen in 5/38 (13%) patients. The MTD was set at 1.5 mg/kg in arm B and was not reached in arm C. RP2D was declared as 1.25 mg/kg for both arms. Depatux-m demonstrated a linear pharmacokinetic profile. In recurrent glioblastoma patients, the progression-free survival (PFS) rate at 6 months was 30.8% and the median overall survival was 10.7 months. Best Response Assessment in Neuro-Oncology responses were 1 complete and 2 partial responses. Conclusion: Depatux-m alone or in combination with temozolomide demonstrated an acceptable safety and pharmacokinetic profile in glioblastoma. Further studies are currently under way to evaluate its efficacy in newly diagnosed (NCT02573324) and recurrent glioblastoma (NCT02343406).


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Glioblastoma/tratamiento farmacológico , Adulto , Anciano , Anticuerpos Monoclonales Humanizados/administración & dosificación , Neoplasias Encefálicas/patología , Femenino , Estudios de Seguimiento , Glioblastoma/patología , Humanos , Inmunoconjugados/administración & dosificación , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Pronóstico , Seguridad , Tasa de Supervivencia , Temozolomida/administración & dosificación , Distribución Tisular , Adulto Joven
11.
Neuro Oncol ; 19(7): 965-975, 2017 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-28039367

RESUMEN

BACKGROUND: The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that preferentially targets tumors expressing overactive epidermal growth factor receptor (EGFR). METHODS: In this multicenter phase I study, patients received 0.5-3.2 mg/kg ABT-414 every 2 weeks by intravenous infusion. EGFR alterations, O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation, and isocitrate dehydrogenase (IDH1) gene mutations were assessed in patient tumors. Distinct prognostic classes were assigned to patients based on a Molecular Classification Predictor model. RESULTS: As of January 7, 2016, forty-five patients were enrolled to receive ABT-414 plus radiation and temozolomide. The most common treatment emergent adverse events were ocular: blurred vision, dry eye, keratitis, photophobia, and eye pain. Ocular toxicity at any grade occurred in 40 patients and at grades 3/4 in 12 patients. RPTD and MTD were set at 2 mg/kg and 2.4 mg/kg, respectively. Among 38 patients with pretreatment tumor tested centrally, 39% harbored EGFR amplification, of which 73% had EGFRvIII mutation. Among patients with available tumor tissue (n = 30), 30% showed MGMT promoter methylation and none had IDH1 mutations. ABT-414 demonstrated an approximately dose proportional pharmacokinetic profile. The median duration of progression-free survival was 6.1 months; median overall survival has not been reached. CONCLUSION: ABT-414 plus chemoradiation demonstrated an acceptable safety and pharmacokinetic profile in newly diagnosed glioblastoma. Randomized studies are ongoing to determine efficacy in newly diagnosed (NCT02573324) and recurrent glioblastoma (NCT02343406).


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/radioterapia , Dacarbazina/análogos & derivados , Glioblastoma/tratamiento farmacológico , Glioblastoma/radioterapia , Inmunoconjugados/uso terapéutico , Adulto , Anciano , Anticuerpos Monoclonales Humanizados/farmacología , Antineoplásicos/farmacología , Biomarcadores de Tumor/metabolismo , Dacarbazina/farmacología , Dacarbazina/uso terapéutico , Supervivencia sin Enfermedad , Quimioterapia Combinada , Femenino , Humanos , Inmunoconjugados/farmacología , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Temozolomida , Resultado del Tratamiento
12.
Cancer Chemother Pharmacol ; 80(6): 1209-1217, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29075855

RESUMEN

PURPOSE: Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody-drug conjugate that preferentially binds cells with EGFR amplification, is internalized and releases a potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, and efficacy of depatux-m monotherapy at the recommended Phase 2 dose (RPTD) in patients with EGFR-amplified, rGBM. METHODS: M12-356 (NCT01800695) is an open-label study with three escalation and expansion cohorts. Sixty-six patients with EGFR-amplified, rGBM were treated with depatux-m monotherapy at 1.25 mg/kg intravenously every 2 weeks. Adults with measurable rGBM, who were bevacizumab-naïve, with EGFR amplification were eligible. RESULTS: Among 66 patients, median age was 58 years (range 35-80). All patients were previously treated with radiotherapy/temozolomide. The most common adverse events (AEs) were eye related (91%), including blurred vision (65%), dry eye (29%), keratitis, and photophobia (27% each). Grade 3/4 AEs occurred in 42% of all patients, and ocular Grade 3/4 AEs occurred in 33% of patients overall. One patient (2%) had a Grade 4 ocular AE. Ocular AEs were manageable and usually resolved once treatment with depatux-m ceased. The objective response rate was 6.8%, the 6-month progression-free survival rate was 28.8%, and the 6-month overall survival rate was 72.5%. CONCLUSION: Depatux-m monotherapy displayed frequent but mostly Grade 1/2 ocular toxicities. A PFS6 of 28.8% was observed in this rGBM population, warranting further study.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Glioblastoma/tratamiento farmacológico , Inmunoconjugados/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Receptores ErbB/genética , Femenino , Glioblastoma/patología , Humanos , Masculino , Persona de Mediana Edad
14.
Eur J Pharmacol ; 684(1-3): 87-94, 2012 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-22504024

RESUMEN

Histamine H(3) receptor antagonists have been widely reported to improve performance in preclinical models of cognition, but more recently efficacy in pain models has also been described. Here, A-960656 ((R)-2-(2-(3-(piperidin-1-yl)pyrrolidin-1-yl)benzo[d]thiazol-6-yl)pyridazin-3(2H)-one) was profiled as a new structural chemotype. A-960656 was potent in vitro in histamine H(3) receptor binding assays (rat K(i)=76 nM, human K(i)=21 nM), and exhibited functional antagonism in blocking agonist-induced [(35)S]GTPγS binding (rat H(3) K(b)=107 nM, human H(3) K(b)=22 nM), and was highly specific for H(3) receptors in broad screens for non-H(3) sites. In a spinal nerve ligation model of neuropathic pain in rat, oral doses of 1 and 3mg/kg were effective 60 min post dosing with an ED(50) of 2.17 mg/kg and a blood EC(50) of 639 ng/ml. In a model of osteoarthritis pain, oral doses of 0.1, 0.3, and 1mg/kg were effective 1h post dosing with an ED(50) of 0.52 mg/kg and a blood EC(50) of 233 ng/ml. The antinociceptive effect of A-960656 in both pain models was maintained after sub-chronic dosing up to 12 days. A-960656 had excellent rat pharmacokinetics (t(1/2)=1.9h, 84% oral bioavailability) with rapid and efficient brain penetration, and was well tolerated in CNS behavioral safety screens. In summary, A-960656 has properties well suited to probe the pharmacology of histamine H(3) receptors in pain. Its potency and efficacy in animal pain models provide support to the notion that histamine H(3) receptor antagonists are effective in attenuating nociceptive processes.


Asunto(s)
Benzotiazoles/farmacología , Antagonistas de los Receptores Histamínicos H3/farmacología , Neuralgia/tratamiento farmacológico , Osteoartritis/tratamiento farmacológico , Piridazinas/farmacología , Receptores Histamínicos H3/metabolismo , Animales , Benzotiazoles/efectos adversos , Benzotiazoles/metabolismo , Benzotiazoles/farmacocinética , Permeabilidad de la Membrana Celular , Inhibidores Enzimáticos del Citocromo P-450 , Modelos Animales de Enfermedad , Perros , Canales de Potasio Éter-A-Go-Go/antagonistas & inhibidores , Células HEK293 , Corazón/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H3/efectos adversos , Antagonistas de los Receptores Histamínicos H3/metabolismo , Antagonistas de los Receptores Histamínicos H3/farmacocinética , Humanos , Masculino , Osteoartritis de la Rodilla/tratamiento farmacológico , Piridazinas/efectos adversos , Piridazinas/metabolismo , Piridazinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Especificidad por Sustrato
15.
Biochem Pharmacol ; 82(8): 967-76, 2011 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-21620806

RESUMEN

Positive modulation of the neuronal nicotinic acetylcholine receptor (nAChR) α4ß2 subtype by selective positive allosteric modulator NS-9283 has shown to potentiate the nAChR agonist ABT-594-induced anti-allodynic activity in preclinical neuropathic pain. To determine whether this benefit can be extended beyond neuropathic pain, the present study examined the analgesic activity and adverse effect profile of co-administered NS-9283 and ABT-594 in a variety of preclinical models in rats. The effect of the combined therapy on drug-induced brain activities was also determined using pharmacological magnetic resonance imaging. In carrageenan-induced thermal hyperalgesia, co-administration of NS-9283 (3.5 µmol/kg, i.p.) induced a 6-fold leftward shift of the dose-response of ABT-594 (ED(50)=26 vs. 160 nmol/kg, i.p.). In the paw skin incision model of post-operative pain, co-administration of NS-9283 similarly induced a 6-fold leftward shift of ABT-594 (ED(50)=26 vs. 153 nmol/kg). In monoiodo-acetate induced knee joint pain, co-administration of NS-9283 enhanced the potency of ABT-594 by 5-fold (ED(50)=1.0 vs. 4.6 nmol/kg). In pharmacological MRI, co-administration of NS-9283 was shown to lead to a leftward shift of ABT-594 dose-response for cortical activation. ABT-594 induced CNS-related adverse effects were not exacerbated in presence of an efficacious dose of NS-9283 (3.5 µmol/kg). Acute challenge of NS-9283 produced no cross sensitization in nicotine-conditioned animals. These results demonstrate that selective positive allosteric modulation at the α4ß2 nAChR potentiates nAChR agonist-induced analgesic activity across neuropathic and nociceptive preclinical pain models without potentiating ABT-594-mediated adverse effects, suggesting that selective positive modulation of α4ß2 nAChR by PAM may represent a novel analgesic approach.


Asunto(s)
Analgésicos/uso terapéutico , Azetidinas/uso terapéutico , Agonistas Nicotínicos/uso terapéutico , Oxadiazoles/uso terapéutico , Dolor/tratamiento farmacológico , Piridinas/uso terapéutico , Receptores Nicotínicos/metabolismo , Regulación Alostérica , Analgésicos/administración & dosificación , Analgésicos/efectos adversos , Animales , Azetidinas/administración & dosificación , Azetidinas/efectos adversos , Conducta Animal/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Quimioterapia Combinada , Imagen por Resonancia Magnética , Masculino , Agonistas Nicotínicos/administración & dosificación , Agonistas Nicotínicos/efectos adversos , Osteoartritis/tratamiento farmacológico , Osteoartritis/metabolismo , Oxadiazoles/administración & dosificación , Oxadiazoles/efectos adversos , Dolor/metabolismo , Piridinas/administración & dosificación , Piridinas/efectos adversos , Ratas , Ratas Sprague-Dawley
16.
Fam Process ; 44(4): 381-98, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16433284

RESUMEN

Family stories have long been recognized as a vehicle for assessing components of a family's emotional and social life, including the degree to which an immigrant family has been willing to assimilate. Transnationalism, defined as living in one or more cultures and maintaining connections to both, is now increasingly common. A qualitative study of family stories in the family of those who appear completely "American" suggests that an affiliation with one's home country is nevertheless detectable in the stories via motifs such as (1) positively connotated home remedies, (2) continuing denigration of home country "enemies," (3) extensive knowledge of the home country history and politics, (4) praise of endogamy and negative assessment of exogamy, (5) superiority of home country to America, and (6) beauty of home country. Furthermore, an awareness of which model--assimilationist or transnational--governs a family's experience may help clarify a clinician's understanding of a family's strengths, vulnerabilities, and mode of framing their cultural experiences.


Asunto(s)
Diversidad Cultural , Familia/psicología , Aculturación , Actitud , Cuba/etnología , Emigración e Inmigración , Amigos , Grecia/etnología , Humanos , Relaciones Interpersonales , Multilingüismo , Proyectos Piloto , Federación de Rusia/etnología , Identificación Social , Percepción Social , Encuestas y Cuestionarios , Estados Unidos
17.
Univ. sci ; 14(2): 141-150, May-Aug. 2009. ilus, tab
Artículo en Español | LILACS-Express | LILACS | ID: lil-637323

RESUMEN

Objetivo. Identificar los grupos de metabolitos secundarios de la Salvia scutellarioides presentes en la fracción que presenta un mayor efecto inhibitorio sobre la actividad de la enzima convertidora de angiotensina (ACE). Materiales y métodos. Se empleó material vegetal seco con el que inicialmente se prepararon extractos etanólicos, luego estos se concentraron y se separaron por cromatografía en columna en diferentes polaridades (éter de petróleo, diclorometano, éter etílico y etanol). Posteriormente se aisló tejido pulmonar de ratas Wistar, el cual fue disgregado y sometido a centrifugación para separar el material soluble. Se separaron las proteínas encontradas en el sobrenadante empleando una columna de Sephacryl; se realizó un pool con las fracciones que presentaron actividad frente al sustrato de la ACE Hippuril-L-histidyl-L-leucine. Con este extracto enzimático fue posible medir el efecto de los extractos vegetales obtenidos de la Salvia scutellarioides sobre la actividad de la ACE. Resultados. La fracción de acetato de etilo (T2) fue la que mostró un mayor efecto inhibitorio sobre la actividad de la ACE. Los metabolitos encontrados en la fracción de T2 fueron: taninos, glicosidos cardiotónicos, cumarinas y quinonas. Conclusión. Se determinó el efecto antihipertensivo para la especie en estudio, por medio de la inhibición de la actividad de la ACE; de igual manera se identificaron varios grupos de metabolitos secundarios presentes en el extracto de T2 que podrían ser los responsables de tal efecto.


Objective. To identify groups of secondary metabolites of Salvia scutellarioides present in the fraction with the greatest inhibitory effect on the activity of the angiotensin-converting enzyme (ACE). Materials and methods. Dry plant material was used to prepare ethanolic extracts that were then concentrated and separated by column chromatography using solvents of different polarity (petroleum ether, dichloromethane, diethyl ether and ethanol). Subsequently, lung tissue isolated from Wistar rats was broken and centrifuged in order to separate the soluble material. Proteins found in the supernatant were separated using a Sephacryl column; a pool was made with the fractions that showed activity with hippuryl-L-histidyl-L-leucine (HHL), the substrate of the ACE. This enzyme extract was used to measure the effect of plant extracts obtained from S. scutellarioides on the ACE activity. Results: The fraction of ethyl acetate (T2) showed a greater inhibitory effect on the ACE activity. Metabolites found in T2 fraction were: tannins, cardiac glycosides, coumarins, and quinones. Conclusion. An antihypertensive effect was found for the plant species Salvia scutellarioides by studying the inhibitory effect on the ACE activity. Several groups of secondary metabolites present in the T2 fraction were identified, which could be responsible for this effect.


Objetivo. Identificar os grupos de metabólitos secundários de Salvia scutellarioides presentes na fração que tem um maior efeito inibitório sobre a atividade da enzima conversora de angiotensina (ECA). Materiais e métodos. Foi utilizado material vegetal seco com o qual inicialmente prepararam-se os extratos etanólicos, depois, estes se concentraram e foram separados por cromatografia em coluna em diferentes polaridades (éter de petróleo, diclorometano, éter etílico e etanol). Posteriormente, foi isolado tecido pulmonar de ratos Wistar, o qual foi desagregado e centrifugado para separar o material solúvel. Foram separadas as proteínas presentes no sobrenadante utilizando uma coluna de Sephacryl; realizou-se um pool com as frações que apresentaram atividade contra o substrato da ACE Hippuril-L-histidil-L-leucine. Com este extrato enzimático foi possível medir o efeito de extratos vegetais obtidos da Salvia scutellarioides sobre a atividade da ACE. Resultados. A fração de acetato de etilo (T2) foi a que apresentou maior efeito inibitório na atividade da ACE. Os metabolitos encontrados na fração do T2 foram: taninos, glicosídeos cardiotónicos, cumarinas e quinonas. Conclusão. Foi determinado o efeito anti-hipertensivo para a espécie em estudo, através da inibição da atividade da ACE, também foram identificados vários grupos de metabólitos secundários presentes no extrato de T2 que poderiam ser responsáveis por este efeito.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA